RBC Raises PTC Therapeutics Price Target to $77 From $75
RBC Capital Markets maintained its Sector Perform rating on PTC Therapeutics. The target change follows the company's third-quarter 2026 results and updated full-year revenue guidance.
RBC Capital Markets maintained its Sector Perform rating on PTC Therapeutics. The target change follows the company's third-quarter 2026 results and updated full-year revenue guidance.